Treating a bacterial skin infection with a whole, leech saliva extract
Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a bacterial skin infection. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.
1. A method of treating a bacterial skin infection of a subject in need thereof, comprising administering an effective amount of a refined, whole leech saliva extract to the skin of the subject, the extract having a peptide molecular weight distribution with molecular weights of 3496 Daltons or greater; wherein the whole leech saliva extract functions as an agent in the treatment of the bacterial skin infection, and wherein the extract is produced from a process comprising:
feeding a phagostimulatory agent to a leech;
inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than 0° C. or about 0° C.; and,
collecting an unrefined, whole saliva in the regurgitation of the cooled leech.
2. The method of claim 1 , further comprising revitalizing the leech by warming the leech in a water bath having a temperature ranging from about 5° C. to about 40° C.
3. The method of claim 1 , wherein the method further comprises creating a refined, whole-saliva extract; the creating including removing solid components from the unrefined, whole saliva.
4. The method of claim 1 , wherein the method further comprises lyophilizing separate volumes of the refined, whole saliva extract, the volumes not exceeding about 2 ml each.
5. The method of claim 1 , the leech being Hirudinaria manillensis.
6. The method of claim 1 , wherein the bacterial infection is selected from the group consisting of anaplasmosis, anthrax, botulism, brucellosis, campylobacteriosis, cellulitis, chancroid, chlamydia, chlamydia trachomatis , cholera, diphtheria, donovanosis, ehrlichiosis, erysipelas, impetigo, shiga toxin- and verocytotoxin-producing Escherichia coli (STEC/VTEC) infection, Escherichia coli 0157:H7 infection, gonococcal infection, gonorrhea, methicillin-resistant Staphylococcus aureus infection (MRSA), Streptococcal infection, syphilis, tetanus, toxic shock syndrome, tularemia, vancomycin intermediate Staph aureus (VISA) infection, Staphylococcus pyogenes infections, vancomycin resistant Staph aureus (VRSA) infection, Shigella infection, and Salmonella infection.
7. The method of claim 1 , wherein the bacterial infection includes a gram-positive bacteria.
8. The method of claim 1 , wherein the bacterial infection includes Bacillus cereus or Staphylococcus aureus.
9. The method of claim 1 , wherein the bacterial infection includes a gram-negative bacteria.
10. A method of treating a bacterial skin infection of a subject in need thereof, comprising administering an effective amount of a refined, whole leech saliva extract to the subject, the extract having a peptide molecular weight distribution with molecular weights of 3496 Daltons or greater; wherein the whole leech saliva extract functions as an agent in the treatment of the bacterial skin infection, wherein the extract is produced from a process comprising:
feeding a phagostimulatory agent to a leech;
inducing regurgitation in the leech, the inducing including placing the leech in an environment having a temperature ranging from about −5° C. to about 15° C.;
collecting an unrefined, whole saliva in the regurgitation of the cooled leech;
removing solid components from the unrefined, whole saliva to create a refined, whole saliva; and,
lyophilizing separate volumes of the refined, whole saliva extract, the volumes not exceeding about 2 ml each.
11. The method of claim 10 , wherein the bacterial infection is selected from the group consisting of anaplasmosis, anthrax, botulism, brucellosis, campylobacteriosis, cellulitis, chancroid, chlamydia, chlamydia trachomatis , cholera, diphtheria, donovanosis, ehrlichiosis, erysipelas, impetigo, shiga toxin- and verocytotoxin-producing Escherichia coli (STEC/VTEC) infection, Escherichia coli 0157:H7 infection, gonococcal infection, gonorrhea, methicillin-resistant Staphylococcus aureus infection (MRSA), Streptococcal infection, syphilis, tetanus, toxic shock syndrome, tularemia, vancomycin intermediate Staph aureus (VISA) infection, Staphylococcus pyogenes infections, vancomycin resistant Staph aureus (VRSA) infection, Shigella infection, and Salmonella infection.
12. The method of claim 10 , wherein the bacterial infection includes a gram-positive bacteria.
13. The method of claim 10 , wherein the bacterial infection includes Bacillus cereus or Staphylococcus aureus.
14. The method of claim 1 , wherein the bacterial infection includes a gram-negative bacteria.
15. The method of claim 1 , wherein the molecular weight distribution of the whole saliva extract ranges from 4276 Daltons to 44386 Daltons.
16. The method of claim 1 , wherein the molecular weight distribution of the whole saliva extract ranges from 6289 Daltons to 14244 Daltons.
17. The method of claim 1 , wherein the molecular weight distribution of the whole saliva extract ranges from 10812 Daltons to 88210 Daltons.
18. The method of claim 1 , wherein the molecular weight distribution of the whole saliva extract ranges from 3496 Daltons to 88210 Daltons.